1. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 Sep 15 [cited 2022 Dec 26];140(11):1229–53. Available from: https://ashpublications.org/blood/article/140/11/1229/485458/The-International-Consensus-Classification-of.
2. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022 36:7. 2022 Jun 22 [cited 2022 Dec 26];36(7):1720–48. Available from: https://www.nature.com/articles/s41375-022-01620-2.
3. Longo DL, Sehn LH, Salles G. Diffuse large B-cell lymphoma. Longo DL, editor. https://doi.org/10.1056/NEJMra2027612. 2021 Mar 3 [cited 2022 Apr 1];384(9):842–58. Available from: https://www.nejm.org/doi/full/10.1056/NEJMra2027612.
4. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010 Sep 23 [cited 2019 Oct 18];116(12):2040–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20548096.
5. Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011 Oct [cited 2019 Oct 18];12(11):1013–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21940214.